Eco Bright Future, Inc.'s Director, Tomax Strgar, Provides a Letter to Shareholders
February 08, 2024 09:45 ET | Eco Bright Future, Inc.
Eco Bright Future, Inc.'s Director, Tomax Strgar, Provides a Letter to Shareholders
African Demographics
8B Education Investments launches $111,600,000 initiative to Finance African student education at The Clinton Global Initiative
September 20, 2022 10:49 ET | 8B Finance
New York, NY, Sept. 20, 2022 (GLOBE NEWSWIRE) -- 8B Education Investments partners with Nelnet Bank in the first ever lending program by a US bank to African students enrolled in American...
Photo 1
Fattah Neuroscience Global Advisors Develops International Partnership to Build African Neuroscience
January 24, 2022 22:24 ET | Fattah Neuroscience Global Advisors
Philadelphia, Jan. 24, 2022 (GLOBE NEWSWIRE) -- Recently, Fattah Neuroscience Global Advisors LLC (FNGA), a consulting firm founded by former U.S. Congressman Chaka Fattah, Sr., committed to...
Supreme Council of the Arab-African Economy/Resverlogix Corp. Collaboration
Resverlogix Enters into a Cooperation Agreement with the Supreme Council of the Arab-African Economy to Support the Development of Apabetalone for COVID-19 Patients
November 03, 2021 08:00 ET | Resverlogix Corp
CALGARY, Alberta, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the Company”) (TSX: RVX), a world leader in epigenetics or gene regulation, is pleased to announce today that...
Hammer NEW LOGO.jpg
Hammer Expands its SMS and Over-the-Top Services PISCATAWAY, N.J., July 16, 2019 (GLOBE NEWSWIRE) -- Hammer Fiber Optics Holdings Corp’s (OTCQB: HMMR) announced today that it has expanded its Over-the-Top services. The 1P-SMSC, offered by Hammer’s...
CORRECTING and REPLACING: Immune Therapeutics, Inc.
May 22, 2017 09:24 ET | Immune Therapeutics, Inc.
In a release issued under the same headline earlier today by Immune Therapeutics, Inc. (OTCQB:IMUN), the headline has been corrected to read "Immune Therapeutics Announces NAFDAC Approval...
Immune Therapeutics Announces NAFDAC Approval of Lodonal™ for the Treatment of HIV in Nigeria
May 22, 2017 08:42 ET | Immune Therapeutics, Inc.
Highlights: National Agency for Food and Drug Administration and Control (“NAFDAC”) approval paves way for Immune Therapeutics’ first significant revenue channel Immune Therapeutics’ goal to capture...
Immune Therapeutics, Inc. Files Lodonal New Drug Application in Kenya
April 25, 2017 11:37 ET | Immune Therapeutics, Inc.
ORLANDO, Fla., April 25, 2017 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTCQB:IMUN), a clinical-stage biopharmaceutical company developing therapies for a range of conditions using LodonalTM...
Immune Therapeutics, Inc. Strengthens Balance Sheet With Debt Settlement
April 12, 2017 13:36 ET | Immune Therapeutics, Inc.
ORLANDO, Fla., April 12, 2017 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTCQB:IMUN), a clinical-stage biopharmaceutical company developing therapies for a range of conditions using LodonalTM,...
Immune Therapeutics Clears Critical Regulatory Hurdle for Lodonal in Kenya
March 17, 2017 09:07 ET | Immune Therapeutics, Inc.
ORLANDO, Fla., March 17, 2017 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTCQB:IMUN), a clinical-stage biopharmaceutical company developing therapies for a range of conditions using Lodonal™,...